japan-ma-prescription-for-growth

Japan M&A: Prescription for growth

The cross-border acquisitions that JapanÆs pharmaceutical companies are announcing could be just what the doctor ordered, even though they come with hefty price tags.

Japanese pharmaceutical companies some of the most sophisticated and cash-rich in the world are shopping abroad for targets to enrich their drug pipelines and counter the uncertain outlook for sales in Japan. But sellers are still insisting on hefty price-tags, despite slowing economic growth and depressed equity markets.

On the face of it, Japan’s greying population looks like good news for the country's pharma businesses. More than one-fifth of Japanese people are over 65 and, according to the CIA World Factbook, the country has the world’s third longest life expectancy at 82 years. But these positive demographics are not providing Japanese drug-makers with the earnings bonanza they may have hoped...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222